A5086957128- Rheumatoid Arthritis Research and Therapies
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Systemic Lupus Erythematosus Research
- Autoimmune and Inflammatory Disorders Research
- Sarcoidosis and Beryllium Toxicity Research
- Lymphoma Diagnosis and Treatment
- Chronic Disease Management Strategies
- IL-33, ST2, and ILC Pathways
- Chronic Lymphocytic Leukemia Research
- Gout, Hyperuricemia, Uric Acid
- Systemic Sclerosis and Related Diseases
- Hepatitis C virus research
- Monoclonal and Polyclonal Antibodies Research
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Spondyloarthritis Studies and Treatments
- Osteoarthritis Treatment and Mechanisms
- Case Reports on Hematomas
- Liver Disease Diagnosis and Treatment
- Biosimilars and Bioanalytical Methods
- Immune cells in cancer
- Inflammatory Myopathies and Dermatomyositis
- Asthma and respiratory diseases
- Occupational exposure and asthma
- Health Systems, Economic Evaluations, Quality of Life
- Bone and Joint Diseases
University of Nebraska Medical Center
2016-2025
VA Nebraska Western Iowa Health Care System
2016-2025
United States Department of Veterans Affairs
2020-2025
University of North Carolina at Chapel Hill
2021-2024
AID Atlanta
2024
American College of Rheumatology
2020-2024
Emory University
2021-2024
Convergence
2024
Durham VA Medical Center
2021-2024
University of Washington
2023
There is no consensus on which comorbidity index optimal for rheumatic health outcomes research. We compared a new Rheumatic Disease Comorbidity Index (RDCI) with the Charlson-Deyo (CDI), Functional (FCI), Elixhauser Total Score (ETS), Point System (EPS), and simple count (COUNT) using US cohort of rheumatoid arthritis (RA) patients.Using administrative diagnostic codes patient self-reporting, we tested predictive values RDCI, CDI, FCI, ETS, EPS, COUNT 2 outcomes: all-cause mortality...
Patients with rheumatic diseases such as rheumatoid arthritis (RA) and lupus have increased risk of infection are treated medications that may increase this yet also hypothesized to help treat COVID-19. We set out understand how the COVID-19 pandemic has impacted lives these patients in United States.
Objective Rheumatoid arthritis (RA) and its treatments are associated with an increased risk of infection, but it remains unclear whether these factors have impact on the or severity COVID‐19. The present study was undertaken to assess COVID‐19 in a US Department Veterans Affairs (VA) cohort patients RA those without RA. Methods A matched using national VA data conducted. Patients diagnosed as having were identified among nondeceased individuals who active health care system January 1, 2020...
There has been limited investigation into cause-specific mortality and the associated risk factors in men with rheumatoid arthritis (RA). We investigated all-cause RA, examining determinants of survival.Men from a longitudinal RA registry were followed enrollment until death or through 2013. Vital status cause determined using National Death Index. Crude rates standardized ratios (SMRs) calculated for all-cause, cardiovascular disease (CVD), cancer, respiratory mortality. Associations...
BackgroundThe relative efficacy and safety of allopurinol febuxostat when used according to current guidelines for the treatment hyperuricemia are unknown. This double-blind noninferiority trial examined these issues.MethodsParticipants with gout (with at least 33% having stage 3 chronic kidney disease) were randomly assigned or in this 72-week trial, doses titrated target serum urate. The had three phases: titration (weeks 0 24), maintenance 25 48), observation 49 72). Allopurinol initiated...
Abstract Objectives To determine whether RA and interstitial lung disease (ILD) severity measures are associated with survival in patients RA-ILD. Methods We studied US veterans RA-ILD participating a multicentre, prospective cohort study. activity (28-joint DAS [DAS28-ESR]) functional status (multidimensional HAQ [MDHAQ]) were collected longitudinally while pulmonary function tests (forced vital capacity [FVC], diffusing for carbon monoxide) obtained from medical records. Vital cause of...
Objective To evaluate the associations of plasma matrix metalloproteinases (MMPs) with prevalent and incident interstitial lung disease (ILD) in people rheumatoid arthritis (RA). Methods Within a multicenter, prospective cohort US veterans RA, we performed cross‐sectional study ILD ILD. diagnoses were validated by medical record review provider chest imaging and/or pathology reports. MMP‐1, 3, 7, 9 concentrations measured samples, then standardized categorized into quartiles. The MMPs...
The C-reactive protein (CRP) level and erythrocyte sedimentation rate (ESR) are important disease activity biomarkers in rheumatoid arthritis (RA). This study aimed to determine what extent obesity biases these biomarkers.Body mass index (BMI) associations with CRP ESR were assessed 2 RA cohorts: the cross-sectional Body Composition (BC) cohort (n = 451), including whole-body dual x-ray absorptiometry measures of fat index; longitudinal Veterans Affairs Rheumatoid Arthritis (VARA) registry...
Objective To compare serum anti–malondialdehyde–acetaldehyde (anti‐ MAA ) antibody levels and expression in lung tissue from patients with rheumatoid arthritis–associated interstitial disease (RA‐ILD) to those found controls. Methods Anti‐ (IgA, IgM, IgG) concentrations were measured RA‐ILD compared of RA chronic obstructive pulmonary ( COPD without disease. Associations between anti‐ assessed using multivariable logistic regression. Lung , other ILD or emphysema, controls (n = 3 per group)...
To determine if body mass index (BMI) and adipokine levels identify rheumatoid arthritis (RA) patients most likely to benefit from initiation of tumour necrosis factor inhibitors (TNFi) after methotrexate inadequate response.
Although clinical and genetic risk factors have been identified for rheumatoid arthritis-associated interstitial lung disease (RA-ILD), there are no current tools allowing stratification. We sought to develop validate an ILD model in a large, multicentre, prospective RA cohort.
Objective We aimed to evaluate lung cancer risk in patients with rheumatoid arthritis (RA) and RA‐interstitial disease (ILD). Methods performed a retrospective, matched cohort study of RA RA‐ILD within the Veterans Health Administration (VA) between 2000 2019. Patients were identified validated administrative‐based algorithms, then (up 1:10) on age, gender, VA enrollment year individuals without RA. Lung cancers from oncology database National Death Index. Conditional Cox regression models...
The objective of this study is to examine the risk serious infections (SIs) associated with biological disease-modifying antirheumatic drugs (bDMARDs) compared conventional synthetic (csDMARDs) in patients rheumatoid arthritis (RA).We studied RA who initiated bDMARDs or csDMARDs from 2001 2016 FORWARD-The National Databank for Rheumatic Diseases. Disease-modifying (DMARDs) were categorized into three groups: (1) (bDMARD-naïve; reference), (2) tumor necrosis factor α inhibitors (TNFis), and...
Interstitial lung disease (ILD) is a frequent complication of rheumatoid arthritis (RA), occurring in up to 40% patients during the course their disease. Early diagnosis critical, particularly given shared clinicoepidemiologic features between advanced arthritis-associated ILD (RA-ILD) and idiopathic pulmonary fibrosis (IPF). This study was undertaken define molecular basis this overlap through comparative profiling serum proteins RA-ILD IPF.Multiplex enzyme-linked immunosorbent assays...